Related Experiment Video

Updated: Aug 26, 2025

Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae
09:05

Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae

Published on: April 18, 2016

29.2K

The impact of cycleanine in cancer research: a computational study

Ogochukwu Ngozi Nwaefulu1, Nizar A Al-Shar'i2, Josephine Omonkhelin Owolabi3

  • 1Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.

Journal of Molecular Modeling
|October 4, 2022
PubMed

Insights

Cycleanine, a natural product, may inhibit the poly (ADP-ribose) polymerase 1 (PARP1) enzyme, a key factor in cancer development. This study computationally suggests cycleanine as a potential new anticancer agent by exploring its interaction with PARP1.

Area of Science:

  • Pharmacology
  • Computational Chemistry
  • Oncology

Background:

  • Cancer presents a significant global health challenge, with existing treatments facing limitations like resistance and severe side effects.
  • Natural products offer a promising avenue for discovering novel anticancer agents with improved efficacy and safety profiles.
  • Poly (ADP-ribose) polymerase 1 (PARP1) is implicated in carcinogenesis, and its inhibitors are established anticancer drugs.

Purpose of the Study:

  • To computationally investigate the cytotoxic activity of the natural product cycleanine.
  • To determine if cycleanine acts as a PARP1 inhibitor or a caspase activator.
  • To explore the potential of cycleanine as a novel anticancer therapeutic.

Main Methods:

  • Utilized molecular docking simulations to assess the binding affinity of cycleanine to PARP1.
  • Employed molecular dynamics (MD) simulations to analyze the stability of the cycleanine-PARP1 complex.
  • Evaluated the cytotoxic potential of cycleanine against cancer cells.

Main Results:

  • Cycleanine demonstrated significant binding affinity to the PARP1 enzyme.
  • Molecular dynamics simulations confirmed the formation of a stable complex between cycleanine and PARP1.
  • The findings suggest cycleanine's potential as a PARP1 inhibitor.

Conclusions:

  • Cycleanine exhibits potential as a PARP1 inhibitor, warranting further investigation for anticancer applications.
  • Computational methods provide valuable insights into the mechanism of action for natural product-derived drug candidates.
  • Cycleanine represents a promising lead compound for the development of new anticancer therapies targeting PARP1.
Keywords:
Antiproliferative activityCaspase-3CycleanineCytotoxicityMolecular dynamics simulationPARP1 inhibitor

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K